AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteRasagiline is a selective irreversible inhibitor of MAO-B (monoamine oxidase-B).
More Information Supplier PageRasagiline is a selective irreversible inhibitor of MAO-B (monoamine oxidase-B).
More Information Supplier PageRasagiline is an irreversible inhibitor of monoamine oxidase used as a monotherapy in early Parkinson’s disease or as an adjunct therapy in more advanced cases. It is selective for MAO type B over type A by a factor of fourteen.
More Information Supplier PageRasagiline is an irreversible inhibitor of monoamine oxidase used as a monotherapy in early Parkinson’s disease or as an adjunct therapy in more advanced cases. It is selective for MAO type B over type A by a factor of fourteen.
More Information Supplier PageRasagiline is an irreversible inhibitor of monoamine oxidase used as a monotherapy in early Parkinson’s disease or as an adjunct therapy in more advanced cases. It is selective for MAO type B over type A by a factor of fourteen.
More Information Supplier PageRauwolscine is a natural alkaloid that acts as a selective and reversible α2-adrenergic receptor antagonist (Ki = 12 nM).
More Information Supplier PageRauwolscine is a natural alkaloid that acts as a selective and reversible α2-adrenergic receptor antagonist (Ki = 12 nM).
More Information Supplier PageRavuconazole is an ergosterol biosynthesis inhibitor and antifungal agen
More Information Supplier PageRavuconazole is an ergosterol biosynthesis inhibitor and antifungal agen
More Information Supplier PageRavuconazole is an ergosterol biosynthesis inhibitor and antifungal agen
More Information Supplier PageRavuconazole is an ergosterol biosynthesis inhibitor and antifungal agen
More Information Supplier PageRazaxaban is a selective, potent, and orally bioavailable inhibitor of coagulation factor Xa.
More Information Supplier PageRazaxaban is a selective, potent, and orally bioavailable inhibitor of coagulation factor Xa.
More Information Supplier PageRazaxaban is a selective, potent, and orally bioavailable inhibitor of coagulation factor Xa.
More Information Supplier PageRazaxaban is a selective, potent, and orally bioavailable inhibitor of coagulation factor Xa.
More Information Supplier PageRC-3095 is a bombesin/gastrin-releasing peptide (BN/GRP) antagonist with potential anticancer activity.
More Information Supplier PageRC-3095 is a bombesin/gastrin-releasing peptide (BN/GRP) antagonist with potential anticancer activity.
More Information Supplier PageRC-3095 is a bombesin/gastrin-releasing peptide (BN/GRP) antagonist with potential anticancer activity.
More Information Supplier PageRC-3095 is a bombesin/gastrin-releasing peptide (BN/GRP) antagonist with potential anticancer activity.
More Information Supplier PageReboxetine mesylate is a potent and selective inhibitor of SLC6A2 noradrenalin uptake (Ki values are 1.1, 129 and > 1N/A,N/AN/AN/A nM for rat SLC6A2, ST, and DAT, respectively).
More Information Supplier PageReboxetine mesylate is a potent and selective inhibitor of SLC6A2 noradrenalin uptake (Ki values are 1.1, 129 and > 1N/A,N/AN/AN/A nM for rat SLC6A2, ST, and DAT, respectively).
More Information Supplier PageReboxetine mesylate is a potent and selective inhibitor of SLC6A2 noradrenalin uptake (Ki values are 1.1, 129 and > 1N/A,N/AN/AN/A nM for rat SLC6A2, ST, and DAT, respectively).
More Information Supplier PageReboxetine mesylate is a potent and selective inhibitor of SLC6A2 noradrenalin uptake (Ki values are 1.1, 129 and > 1N/A,N/AN/AN/A nM for rat SLC6A2, ST, and DAT, respectively).
More Information Supplier PageReboxetine mesylate is a potent and selective inhibitor of SLC6A2 noradrenalin uptake (Ki values are 1.1, 129 and > 1N/A,N/AN/AN/A nM for rat SLC6A2, ST, and DAT, respectively).
More Information Supplier PageRefametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity.
More Information Supplier PageRefametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity.
More Information Supplier PageRefametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity.
More Information Supplier PageRefametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity.
More Information Supplier PageRefametinib is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.
More Information Supplier PageRefametinib is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.
More Information Supplier PageRefametinib is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.
More Information Supplier PageRefametinib is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.
More Information Supplier PageRegorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
More Information Supplier PageRegorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
More Information Supplier PageRegorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
More Information Supplier PageRegorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFR??, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
More Information Supplier PageRegorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFR??, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
More Information Supplier PageRegorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFR??, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
More Information Supplier PageRemogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney.
More Information Supplier PageRemogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney.
More Information Supplier Page
